Catheter Precision, Inc.

For the period ended Sep 30, 2025. Filed Nov 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 13, 2025

VTAK$0.15-0.7%Stored close · as of Oct 2, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

Condensed Consolidated Statements of Stockholders' Equity

(in thousands, except share data)

Total
Series A Convertible Preferred Stock · Series B Convertible Preferred Stock · Series X Convertible Preferred Stock · Common Stock · Additional Paid-In · Accumulated · Catheter Precision Inc. Stockholders' · Non-controlling · Total Stockholders'
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Deficit	Equity	Interest	Equity
Balance at December 31, 2024	—	$—	—	$—	12,656	$—	421,296	$—	$304,109	$(292,352)	$11,757	$—	$11,757
Stock-based compensation	—	—	—	—	—	—	—	—	91	—	91	—	91
Issuance of common stock for vested restricted stock awards	—	—	—	—	—	—	2,631	—	—	—	—	—	—
Issuance of common stock for asset acquisition (see Note 14)	—	—	—	—	—	—	14,473	—	113	—	113	—	113
Issuance of common stock upon release of Prepaid Series Warrants (see Note 11)	—	—	—	—	—	—	49,421	—	—	—	—	—	—
Net loss	—	—	—	—	—	—	—	—	—	(4,045)	(4,045)	—	(4,045)
Balance at March 31, 2025	—	—	—	—	12,656	—	487,821	—	304,313	(296,397)	7,916	—	7,916
Stock-based compensation	—	—	—	—	—	—	—	—	98	—	98	—	98
Issuance of common stock for vested restricted stock awards	—	—	—	—	—	—	2,632	—	—	—	—	—	—
Issuance of common stock for asset acquisition (see Note 14)	—	—	—	—	—	—	52,631	—	280	—	280	—	280
Issuance of common stock upon release of Prepaid Series Warrants (see Note 11)	—	—	—	—	—	—	113,526	—	—	—	—	—	—
Issuance of preferred stock and warrants under the May 2025 PIPE Financing, net of issuance costs	—	—	3,000	—	—	—	—	—	2,034	—	2,034	—	2,034
Issuance of common stock upon the ATM Offering, net of issuance costs	—	—	—	—	—	—	220,185	—	1,570	—	1,570	—	1,570
Conversion of preferred stock	—	—	(771)	—	—	—	115,913	—	—	—	—	—	—
Issuance of VIE shares to non-controlling interest	—	—	—	—	—	—	—	—	—	—	—	109	109
Net loss	—	—	—	—	—	—	—	—	—	(5,109)	(5,109)	(349)	(5,458)
Balance at June 30, 2025	—	—	2,229	—	12,656	—	992,708	—	308,295	(301,506)	6,789	(240)	6,549
Stock-based compensation	—	—	—	—	—	—	—	—	70	—	70	—	70
Issuance of common stock for vested restricted stock awards	—	—	—	—	—	—	6,000	—	—	—	—	—	—
Issuance of common stock upon the ATM Offering, net of issuance costs	—	—	—	—	—	—	648,397	—	2,174	—	2,174	—	2,174
Net loss	—	—	—	—	—	—	—	—	—	(2,251)	(2,251)	(93)	(2,344)
Balance at September 30, 2025	—	$—	2,229	$—	12,656	$—	1,647,105	$—	$310,539	$(303,757)	$6,782	$(333)	$6,449

Total
Series A Convertible Preferred Stock · Series B Convertible Preferred Stock · Series X Convertible Preferred Stock · Common Stock · Additional Paid-In · Accumulated · Catheter Precision Inc. Stockholders' · Non-controlling · Total Stockholders'
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Deficit	Equity	Interest	Equity
Balance at December 31, 2023	4,578	$—	—	$—	12,656	$—	36,993	$—	$296,902	$(275,709)	$21,193	$—	$21,193
Stock-based compensation	—	—	—	—	—	—	—	—	6	—	6	—	6
Conversion of Series A Convertible Preferred Stock	(875)	—	—	—	—	—	2,877	—	—	—	—	—	—
Net loss	—	—	—	—	—	—	—	—	—	(2,675)	(2,675)	—	(2,675)
Balance at March 31, 2024	3,703	—	—	—	12,656	—	39,870	—	296,908	(278,384)	18,524	—	18,524
Stock-based compensation	—	—	—	—	—	—	—	—	13	—	13	—	13
Net loss	—	—	—	—	—	—	—	—	—	(4,220)	(4,220)	—	(4,220)
Balance at June 30, 2024	3,703	—	—	—	12,656	—	39,870	—	296,921	(282,604)	14,317	—	14,317
Issuance of common stock and other equity-classified contracts from September 2024 Public Offering, net of issuance costs	—	—	—	—	—	—	42,415	—	2,612	—	2,612	—	2,612
Issuance of common stock upon exercise of Pre-Funded Warrants (see Note 11)	—	—	—	—	—	—	87,261	—	—	—	—	—	—
Conversion of Series A Convertible Preferred Stock	(3,703)	—	—	—	—	—	12,177	—	—	—	—	—	—
Stock-based compensation	—	—	—	—	—	—	—	—	17	—	17	—	17
Net loss	—	—	—	—	—	—	—	—	—	(4,120)	(4,120)	—	(4,120)
Balance at September 30, 2024	—	$—	—	$—	12,656	$—	181,723	$—	$299,550	$(286,724)	$12,826	$—	$12,826

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.